New scan could reveal if chemo is working in just weeks

NCT ID NCT03822312

Ongoing Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple-negative breast cancer who are receiving chemotherapy before surgery. If the scan works, it could help doctors know sooner whether to continue or change treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DBT-TOBI scan (device)
What this could lead to: If successful, this scan could help doctors know early whether chemotherapy is working for breast cancer patients, allowing them to adjust treatment sooner.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to everyone. The scan is still experimental and not yet proven to be reliable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.